Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS

(NRG Oncology) The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43. The trial did find a statistically non-significant, modest (19%) reduction in the rate of recurrence among women that received trastuzumab, but this difference was not statistically significant.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Turk J Med Sci. 2021 Sep 8. doi: 10.3906/sag-2103-148. Online ahead of print.ABSTRACTBACKGROUND/AIM: Paget?s disease (PD) of the breast is a very rare presentation of breast malignancy, accounting for 1?3% of all primary breast tumors. We aimed to evaluate and compare the clinicopathological featuresand clinical outcome of PD accompanied by in situ carcinoma and invasive cancer.MATERIALS AND METHODS: We used the archive of our pathology laboratory retrospectively for age, gender, history of surgery, histopathological findings, treatment modalities and follow-up information. We used the Kaplan-Meier method for survival anal...
Source: Turkish Journal of Medical Sciences - Category: General Medicine Authors: Source Type: research
This study aimed to evaluate the expression and prognostic significance of glutaminase in luminal breast cancer (BC). The glutaminase isoforms (GLS/GLS2) were assessed at genomic/transcriptomic levels, using METABRIC (n = 1398) and GeneMiner datasets (n = 4712), and protein using immunohistochemistry in well-characterised cohorts of Oestrogen receptor-positive/HER2-negative BC patients: ductal carcinoma in situ (DCIS; n = 206) and invasive breast cancer (IBC; n = 717). Glutaminase expression was associated with clinicopathological features, patient outcome and glutamine-metabolism-related genes. In DCIS, GLS alone and GLS+...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Ann Surg Oncol. 2021 Jul 1. doi: 10.1245/s10434-021-10378-3. Online ahead of print.ABSTRACTBACKGROUND: Because no prior studies have evaluated the chronological trends of ductal carcinoma in situ (DCIS) despite the increasing number of surgeries performed for DCIS, this study analyzed how the clinical, radiologic, and pathologic characteristics of DCIS changed during a 10-year period.METHODS: Of 7123 patients who underwent primary breast cancer surgery at a single institution from 2006 to 2015, 792 patients with pure DCIS were included in this study. The chronological trends of age, symptoms, method for detecting either ma...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Source Type: research
Contributors : Joshua D Ginzel ; Chaitanya R Acharya ; Veronica Lubkov ; Hidetoshi Mori ; Peter G Boone ; Lauren K Rochelle ; Wendy Roberts ; Zachary C Hartman ; Erika Crosby ; Jeffrey I Everitt ; Lawrence S Barak ; Marc G Caron ; Jane Q Chen ; Neil E Hubbard ; Robert D Cardiff ; Alexander D Borowsky ; H K Lyerly ; Joshua C SnyderSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe sequential accumulation of survival advantage traits – the cancer evolution hypothesis – implies that early detection and treatment of precancers can prevent cancer mortality. In practice, detect...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
ConclusionsAs DCIS can respond to NST containing HER2-blockade, the presence of extensive DCIS in HER2-positive breast cancer before NST should not always indicate a mastectomy. The predictive factors we found could be helpful when considering breast-conserving surgery in these patients.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractPurpose of reviewMost women undergoing breast conservation surgery (BCS) for ductal carcinoma in situ (DCIS) receive breast radiotherapy (RT) to reduce the incidence of ipsilateral recurrent DCIS and development of invasive disease. This review seeks to appraise the potential for de-escalation of RT based on clinical, biomarker, and/or molecular testing.Recent findingsClinical prognostic factors have highlighted young age, tumor (DCIS) size, multifocality, DCIS grade, palpability, and immunohistochemical biomarkers (ER negative, HER2 positive) as prognostic factors. However, molecular markers including the Oncotype...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
CONCLUSION: As reported in other countries, breast cancer in LFS patients in South Korea had an early onset and were predominantly but not exclusively positive for HER2. A multidisciplinary approach with adherence to the treatment guidelines, considering mastectomy, and avoiding RT is encouraged to prevent RT-associated sequelae in LFS patients.PMID:33818021 | DOI:10.4048/jbc.2021.24.e16
Source: Journal of Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | Clinical Trials | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | HER2 | Herceptin | Statistics | Women